uniQure N.V. (QURE)
Stock Price:
$39.10 USD
1.56 (4.16%)
Updated Oct 20, 2020 2:22 PM EDT - Market open
Key Info
| Market Cap |
1.74B |
| Revenue (ttm) |
5.31M |
| Net Income (ttm) |
-135.58M |
| Shares Out |
44.45M |
| EPS (ttm) |
-3.13 |
| PE Ratio |
n/a |
| Forward PE |
26.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$39.10 |
| Previous Close |
$37.54 |
| Change ($) |
1.56 |
| Change (%) |
4.16% |
| Day's Open |
37.67 |
| Day's Range |
37.60 - 39.24 |
| Day's Volume |
337,357 |
| 52-Week Range |
34.38 - 76.69 |
More Stats
| Market Cap |
1.74B |
| Enterprise Value |
1.49B |
| Earnings Date (est) |
Nov 3, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.45M |
| Float |
35.22M |
| EPS (basic) |
-3.14 |
| EPS (diluted) |
-3.13 |
| FCF / Share |
-2.65 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.00M |
| Short Ratio |
8.99 |
| Short % of Float |
11.36% |
| Beta |
1.12 |
| PE Ratio |
n/a |
| Forward PE |
26.46 |
| P/FCF Ratio |
n/a |
| PS Ratio |
327.28 |
| PB Ratio |
6.16 |
| Revenue |
5.31M |
| Operating Income |
-139.51M |
| Net Income |
-135.58M |
| Free Cash Flow |
-117.58M |
| Net Cash |
243.12M |
| Net Cash / Share |
5.47 |
| Gross Margin |
-1,647.01% |
| Operating Margin |
-2,627.33% |
| Profit Margin |
-2,553.30% |
| FCF Margin |
-2,214.35% |
| ROA |
-26.82% |
| ROE |
-68.21% |
| ROIC |
-123.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (16)
| Buy |
11 |
| Overweight |
2 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$72.50*
(85.42% upside)
Low
52.0
Current: $39.10
High
91.0
Target: 72.50
*Average 12-month price target from 14 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 7.28 | 11.28 | 13.11 | 25.10 | 10.58 | 6.14 |
| Revenue Growth | -35.48% | -13.91% | -47.78% | 137.27% | 72.25% | - |
| Gross Profit | 7.28 | 11.28 | 13.11 | 25.10 | 10.58 | 6.14 |
| Operating Income | -123 | -90.38 | -86.77 | -73.41 | -71.93 | -54.70 |
| Net Income | -124 | -83.30 | -79.26 | -73.37 | -82.08 | -49.78 |
| Shares Outstanding | 40.00 | 35.64 | 26.98 | 25.04 | 22.08 | 17.12 |
| Earnings Per Share | -3.11 | -2.34 | -2.94 | -2.93 | -3.72 | -2.91 |
| Operating Cash Flow | -98.68 | -76.04 | -64.27 | -72.19 | 7.47 | -36.85 |
| Capital Expenditures | -5.65 | -2.38 | -4.46 | -15.29 | -7.61 | -22.20 |
| Free Cash Flow | -104 | -78.42 | -68.73 | -87.48 | -0.14 | -59.05 |
| Cash & Equivalents | 378 | 235 | 159 | 132 | 222 | - |
| Total Debt | 73.06 | 35.47 | 20.79 | 20.24 | 20.21 | - |
| Net Cash / Debt | 305 | 199 | 139 | 112 | 201 | - |
| Assets | 449 | 274 | 210 | 190 | 263 | - |
| Liabilities | 126 | 94.30 | 120 | 127 | 135 | - |
| Book Value | 323 | 180 | 89.36 | 63.63 | 128 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
uniQure N.V. |
| Country |
Netherlands |
| Employees |
248 |
| CEO |
Matthew C. Kapusta |
Stock Information
| Ticker Symbol |
QURE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: QURE |
| IPO Date |
June 20, 2007 |
Description
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.